The FreeStyle Libre 2 system, the second generation of Abbott’s sensor-based technology for people living with diabetes, has been approved and added to the NHS Drug Tariff for England, Scotland, Wales and Northern Ireland from 1st November.
The FreeStyle Libre 2 system, with optional real-time alarms, has been given the go-ahead by the NHS Business Services Authority for inclusion on the tarif. This means it will now be available on prescription to patients currently on the current FreeStyle Libre system as well as new patients with diabetes who meet the NHS criteria. The GP prescribing system network needs to be updated, with wide availability expected by January 2021.
All current users of the FreeStyle Libre system are advised to speak to their healthcare team from January 2021 to discuss voluntary replacement. New patients should also consult their healthcare team from that time, to discuss suitability and eligibility.
The addition of the FreeStyle Libre 2 system on the NHS Drug Tariff is the latest step in Abbott’s partnership with the NHS in order to be able to ensure Flash glucose monitoring technology is available on prescription.
Please see our earlier news item explaining the current (and coming soon) iteration of FreeStyle Libre sensor family.
To find out more about Libre, click HERE.
